CTOs on the Move

Trumpet Behavioral Health

www.tbh.com

 
TBH is a leading provider of behavioral health services. We specialize in the treatment of children and adults with Autism Spectrum Disorders and developmental disabilities, using the principles of Applied Behavior Analysis (ABA). TBH is proud to employ a talented staff dedicated to its mission and values, constructing a team of experienced, caring and enthusiastic individuals to coordinate the best behavior program possible for children, adults and families. Further, TBH`s collaborative efforts mean that parents, schools, agencies, Supervisors and Skills Trainers all play important roles in behavior programs, forming a large team dedicated to the needs of each client. TBH ...
  • Number of Employees: 250-1000
  • Annual Revenue: $250-500 Million
  • www.tbh.com
  • 390 Union Blvd. Suite 300
    Lakewood, CO USA 80228
  • Phone: 303.989.8169

Executives

Name Title Contact Details

Similar Companies

Diamond Recovery Centers

Diamond Recovery Centers is run by members in recovery, industry-leading professionals, and world-class clinicians. Our mission statement is ” If we put the clients and their needs first, everything else will fall in place”. Our only goal is to help those struggling with Mental Health and Substance Abuse one client at a time.

Protech Dental Studio

Protech Dental Studio is a Sterling, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Arthrex

Arthrex, Inc. is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Arthrex, Inc. is based in Naples, FL. You can find more information on Arthrex, Inc. at www.arthrex.com

Ninos Latinos Unidos

Ninos Latinos Unidos is a Colton, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ovid Therapeutics

Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid`s drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients.